Introduction:Patients with threatened miscarriage associated with adverse pregnancy outcomes because of associated pregnancy and labor complications.Objectives:To evaluate the effect of threatened miscarriage on early and late pregnancy outcome.Methods:A retrospective case–controlled study was performed on 89 women with threatened miscarriage (study group) at Maternity and Children Hospital Buraidah, KSA from January 2010 to December 2010. They were matched for age and parity to 45 cases (control group) attending route antenatal clinic at the same time. Data recorded included, demographic characteristics and detailed pregnancy outcome and ultrasound finding including gestational age, cardiac activity and subchorionic hematoma.Results:The overall adverse pregnancy outcome was significantly higher in the studied cases compared to the control group (p=015).The miscarriage rate was significantly higher in study group compared to the controls group, (16.9%vs 2.2%, p=0000). Preterm delivery, babies with low birth weight and premature rupture of membranes were significantly higher in the miscarriage group compared to the controls group, (15.7% vs 2.2%, p=0.001), (15.7% vs 2.2%), p=0.001) and (6.7%) vs 4.45), p=0.016). There were no significant differences in other pregnancy outcomes.Conclusion:threatened miscarriage is associated with increased incidence of adverse pregnancy outcome. The risk is specially increased in premature rupture of the membranes, preterm delivery and neonatal birth weight.
OBJECTIVE: AMH has been recognized as a useful diagnostic and prognostic tool as a reliable marker of ovarian reserve and predictor of ovarian response to controlled ovarian hyperstimulation. AMH is a member of the transforming growth factor b (TGF-b) superfamily and may be more elevated in endometriosis patients (1) as these growth factors are involved the inflammatory cascade incited by endometriotic lesions. We sought to determine whether AMH levels overestimate actual ovarian response in patients with endometriosis given that AMH is more likely to be elevated in these patients.DESIGN: Retrospective cohort. MATERIALS AND METHODS: Patients participating in their first IVF cycle at a single infertility clinic from 2010-2016 were included. Patients with endometriosis were identified by surgical diagnosis or ultrasound findings consistent with persistent space-occupying disease whose sonographic appearance was consistent with endometriosis. Patients were stratified by SART age group and the number of metaphase II (M2) oocytes retrieved was compared between endometriosis patients and the general IVF population as a function of AMH. Statistical analysis was performed using a student t-test.RESULTS: 639 endometriosis patients and 5619 patients from the general IVF population were analyzed. AMH levels were lower in the endometriosis group overall, 2.8 ng/mL v. 3.4 ng/mL (p¼0.0004). Likewise the number of M2 oocytes was lower in the endometriosis group overall, 8.0AE5.2 v. 8.7AE5.5 oocytes (p¼0.0121). When the groups were stratified by SART age groups as a function of AMH, there was no difference in number of M2 oocytes retrieved between endometriosis patients and the general IVF population (table 1, *p¼NS for all comparisons). Even when AMH was >10 ng/mL or >15 ng/mL, where a difference might be expected, there was no difference in M2 oocytes retrieved.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.